3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
Home-Grown Partnership Pays Dividends
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
You may also be interested in...
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.